民生证券股份有限公司关于 广州安必平医药科技股份有限公司 2022 年限制性股票激励计划 作废部分已授予但尚未归属的限制性股票 之 独立财务顾问报告 二〇二五年四月 1 目录 | 一、释义 … | | --- | | 二、声明 . | | 三、基本假设 … | | 四、独立财务顾问意见 … | | (一 ) 本次限制性股票激励计划已履行的审批程序 | | (二 ) 本次作废限制性股票的具体情况 . | | (三) 结论性意见 . | | 五、备查文件及咨询方式 | | (一) 备查文件 | | (二) 咨询方式… | 2 一、释义 在本独立财务顾问报告中，除非另有所指，下列词语具有如下含义： | 释义项 | | 释义内容 | | --- | --- | --- | | 安必平、本公司、公 | 指 | 广州安必平医药科技股份有限公司 | | 司、上市公司 | | | | 民生证券、独立财务顾 | 指 | 民生证券股份有限公司 | | 问、本独立财务顾问 | | | | 限制性股票激励计划、 | 指 | 《广州安必平医药科技股份有限公司 2022 年限制性股 | | 本激励计划、本计划 | | 票激励计划(草案) ...

法律意见书 关于广州安必平医药科技股份有限公司 2022 年限制性股票激励计划 部分限制性股票作废相关事项的 法律意见书 中国广东深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮编：518038 电话（Tel）：（0755）88265288 传真（Fax）：（0755）88265537 ធ 信達律師事務所 G SUNDIAL LAW FIRM l 法律意见书 释 义 在本法律意见书内，除非文义另有所指，下列简称和词语具有以下含义： | 公司 | 指 | 广州安必平医药科技股份有限公司 | | --- | --- | --- | | 本次激励计划 | 指 | 2022 公司 年限制性股票激励计划 | | 限制性股票 | 指 | 符合本次激励计划授予条件的激励对象，在满足相应归 | | | | 属条件后分次获得并登记的公司股票，为第二类限制性 | | | | 股票 | | 激励对象 | 指 | 根据本次激励计划的相关规定获得限制性股票的公司 （含控股子公司）董事、高级管理人员、核心技术（业 务）人员以及董事会认为需要激励的其他人员（不包括 | | | | 独立董事、监事、单独或合计持有公司 5%以 ...

Group 1: Company Insights - Ziguang Guowei is actively building a second growth curve after the change of its controlling shareholder, focusing on special integrated circuits, intelligent security chips, and quartz crystal frequency devices over the next 3-5 years [1] - The company plans to acquire two firms in 2024 to strengthen its automotive controller chip and intelligent security chip businesses, while also establishing a new company to expand quartz crystal frequency device production [1] - Ziguang Guowei is transferring and deregistering some subsidiaries to concentrate on its core business, with a forecasted significant change in orders for special integrated circuits in 2025, potentially leading to a decrease in gross margin [1] - The company is increasing R&D investment in high-reliability markets and plans to launch more products such as FPGA and memory [1] - Ziguang Guowei intends to repurchase 100-200 million yuan worth of shares for equity incentives or employee stock ownership plans [1] Group 2: AI and Technology Developments - Anbiping is focusing on AI pathology diagnosis, developing an intelligent pathology analysis system to enhance diagnostic accuracy, and has completed multi-center research evaluations for its AI-assisted diagnostic system in collaboration with Tencent ALab [2] - Placo New Materials has launched multiple chip inductor series, gaining validation from several well-known chip manufacturers and is accelerating its mass production and delivery [2] - The company's magnetic powder core products are primarily used in photovoltaic power generation, new energy vehicles, charging piles, data centers, energy storage, communication power supplies, variable frequency air conditioning, power quality rectification, and rail transit [2] Group 3: Institutional Overview - Shanghai Chengrui Investment Management Co., Ltd. was established in May 2010 with a registered capital of 110 million yuan and became a private fund manager in April 2014 [2] - The company focuses on secondary markets and covers major asset allocation strategies, including macro hedging, high-frequency alpha, and CTA strategies, all developed in-house [2] - Chengrui has received multiple industry awards and recognitions, including being ranked among the top private equity firms in China and winning various prestigious awards for its performance [2]

证券研究报告 公司研究 [Table_S 事件：公司发布 ummary]2024 年年报，2024 年实现营业收入 4.71 亿元（yoy-5.33%）， 归母净利润 0.21 亿元（yoy-46.85%），扣非归母净利润 0.14 亿元（yoy- 59.64%），经营活动产生的现金流量净额 0.04 亿元（yoy-79.30%）。其中 2024Q4 实现营业收入 1.18 亿元（yoy-17.28%），归母净利润-0.08 亿元 （yoy-438.62%）。 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 安必平(688393) 投资评级 相关研究 上次评级 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com [Table_Title] AI 加速病理数智化发展，未来增长潜力可期 曹佳琳 医药行业分析师 执业编号：S15005 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on future growth potential [1]. Core Viewpoints - The company reported a slight decline in revenue for 2024, with total revenue of 471 million yuan, down 5.33% year-over-year, and a net profit of 21 million yuan, down 46.85% year-over-year. However, the revenue structure has been optimized, with significant growth in self-produced products, pathology co-construction, and digital products [1][3]. - The company is focusing on enhancing its research and development efforts, particularly in AI and digital pathology, which is expected to improve operational efficiency and diagnostic accuracy. The product matrix is continuously expanding, indicating strong future growth potential [3][4]. - Revenue forecasts for 2025-2027 are optimistic, with expected revenues of 528 million, 610 million, and 710 million yuan, representing year-over-year growth rates of 12.2%, 15.5%, and 16.4%, respectively. Net profit is projected to increase significantly during this period [3][4]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 471 million yuan, a decrease of 5.33% from the previous year. The net profit was 21 million yuan, down 46.85% year-over-year. The gross profit margin for 2024 was 67.23%, a slight decline of 1.26 percentage points [1][4]. - The company’s revenue structure has improved, with notable growth in immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) businesses, which grew by 21.48% and 20.83% year-over-year, respectively. Digital products saw an impressive growth of 80% [3][4]. Research and Development - The company is heavily investing in R&D, focusing on a comprehensive digital pathology diagnostic layout that includes reagents, equipment, and AI. The liquid-based cytology platform has achieved full automation, and the AI-assisted diagnostic products are nearing clinical trial completion [3][4]. Future Projections - The company anticipates revenue growth from 528 million yuan in 2025 to 710 million yuan in 2027, with corresponding net profits expected to rise from 39 million yuan to 65 million yuan during the same period [4].

核心业务承压，HPV产品线受挫 4月21日，安必平（688393）发布2024年年报，公司全年实现营业收入4.71亿元，同比下降5.33%；归属 净利润为2129.13万元，同比大幅下降46.85%；扣非净利润更是暴跌59.64%至1425.38万元。尽管公司在 病理诊断数智化领域取得显著进展，但HPV产品线受集采政策影响，收入同比下降26.95%，成为拖累 业绩的主要因素。 公司开发的宫颈细胞学AI辅助诊断产品在多中心临床研究中表现优异，初级细胞学医生在AI辅助下的 诊断灵敏度由53.1%提升至81.6%，工作量减少37.5%。这一技术不仅提升了诊断效率，还为基层医疗机 构提供了强有力的支持，进一步巩固了安必平在AI医疗领域的领先地位。 此外，病理科共建业务进入高速发展期，收入增速超过90%。公司通过与全国60家基层医院病理科完成 共建项目，以及与23家医联体、专科联盟签订共建协议，进一步扩大了市场渗透率。尽管新增共建点前 期投入较大，但这一业务模式为公司未来的可持续发展奠定了坚实基础。 海外市场布局加速，国际化战略初见成效 安必平在2024年加速了海外市场的布局，选定日本、东南亚和中东地区作为初步目标。报 ...

Core Insights - Anbiping's annual report for 2024 highlights a strategic focus on optimizing revenue structure and enhancing R&D innovation despite facing industry policy adjustments and intensified market competition [1] Group 1: Financial Performance - The company achieved a revenue of 471 million yuan, reflecting a slight year-on-year decline of 5.33%, but with a significant optimization in business structure [1] - Revenue from purchased products decreased by 31.28%, while the proportion of self-produced products continued to rise, strengthening the core business moat [1] - The immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) platforms showed impressive performance, with revenue growth exceeding 20%, becoming new engines for performance growth [1] Group 2: R&D and Product Development - The company invested 60.06 million yuan in R&D, accounting for 12.76% of revenue, focusing on pathology digitization and tumor companion diagnostics [2] - Multiple industry "firsts" were achieved, including the approval of the first domestic FISH platform ALK gene rearrangement detection kit for crizotinib companion diagnostics [2] - The IHC platform developed a complete solution for breast cancer detection, with three types of antibody kits successfully launched, enhancing clinical personalized treatment decisions [2] Group 3: Market Expansion and Strategic Initiatives - The company engaged in a three-in-one model of "remote pathology + digital products + medical testing institutions" to deepen participation in the sinking of medical resources [3] - Revenue from co-construction business increased by 90% year-on-year, with partnerships established with 60 hospitals and agreements with 23 medical alliances [3] - The company completed a comprehensive upgrade of its digital slice scanning system, addressing differentiated needs from grassroots to top-tier hospitals [3] Group 4: International Market Development - The company accelerated its expansion into Japan, Southeast Asia, and the Middle East, obtaining 8 product certificates in Vietnam and 8 CE certificates during the reporting period [4] - Participation in international exhibitions and collaboration with local medical institutions for technology promotion are helping to establish a global access system [4] - The company's integrated solution of "reagents + automated equipment + AI interpretation" is gaining recognition in emerging markets, contributing innovative pathways to address the uneven distribution of pathology resources in developing countries [4]

前十大流通股东累计持有： 5343.89万股，累计占流通股比： 57.12%，较上期变化： 75.00万股。 | 名称 持有数量(万股) | | 占总股本比例 (%) | 增减情况(万股) | | --- | --- | --- | --- | | 蔡向挺 | 1981.70 | 21.18 | 不变 | | 广州市凯多投资咨询中心(有限合伙) | 1295.14 | 13.84 | 不变 | | 诸暨高特佳睿安投资合伙企业(有限合伙) | 562.83 | 6.02 | 不变 | | 南京乾靖创业投资合伙企业(有限合伙) | 348.73 | 3.73 | 不变 | | 广州市达安基因（002030）科技有限公司 | 348.60 | 3.73 | 不变 | | 重庆高特佳睿安股权投资基金合伙企业(有限合 伙) | 240.76 | 2.57 | 不变 | | 朱元元 | 187.14 | 2.00 | 不变 | | 杭州高特佳睿海投资合伙企业(有限合伙) | 148.07 | 1.58 | 不变 | | 李宏卿 | 129.12 | 1.38 | 45.45 | | 张东东 | 101.80 | 1.09 ...

来源：金融界 4月18日，安必平今日收盘28.9元，下跌2.36%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到122.71倍，总市值27.04亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均43.49倍，行业中值29.26倍，安必平排名 第112位。 股东方面，截至2024年9月30日，安必平股东户数6014户，较上次减少593户，户均持股市值35.28万 元，户均持股数量2.76万股。 广州安必平医药科技股份有限公司主要从事体外诊断试剂和仪器的研发、生产和销售。公司主要产品为 肿瘤筛查、诊断试剂、配套设备、数字病理产品、病理能力提升服务。公司建立了覆盖全国31个省（直 辖市、自治区）的营销网络，为全国1,800余家医疗机构提供服务，其中三级以上医院900余家、三甲医 院600余家。公司终端客户包括多家国内权威医院，产品和服务的质量得到客户广泛的认可。 最新一期业绩显示，2024年三季报，公司实现营业收入3.53亿元，同比-0.52%；净利润2963.08万元，同 比-21.18%，销售毛利率68.42%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)112安必平12 ...

Group 1 - The major shareholder, Zhuhai Gaotejia, and its associates held a total of 10,309,059 shares, accounting for 11.0178% of the company's total share capital before the reduction plan [1][2] - The reduction plan allowed for a maximum of 2,806,977 shares to be sold, representing up to 3.00% of the company's total share capital [2] - The actual reduction resulted in the sale of 2,144,897 shares, which is 2.2923% of the total share capital, completed within the disclosed timeframe [2][3] Group 2 - The equity change does not trigger a mandatory tender offer and will not alter the company's controlling shareholder or actual controller [3][5] - The reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [4] - The completion of the reduction plan is expected to have no significant impact on the company's governance structure or future operations [5] Group 3 - In the first quarter of 2025, the company and its subsidiaries obtained 9 domestic medical device registration/filing certificates and 14 intellectual property qualifications [7] - The acquisition of these qualifications is expected to enhance the company's product variety and strengthen its intellectual property protection system, particularly in the fields of tumor screening and precision diagnosis [7]